Design, synthesis and evaluation of PPAR gamma binding activity of 2-thioxo-4-thiazolidinone derivatives

被引:18
作者
Zhou, Li [1 ]
Zhong, Ye [1 ]
Xue, Meng-Zhu [1 ]
Kuang, Dong [1 ]
Cao, Xian-Wen [1 ]
Zhao, Zhen-Jiang [1 ]
Li, Hong-Lin [1 ]
Xu, Yu-Fang [1 ]
Wang, Rui [1 ]
机构
[1] E China Univ Sci & Technol, Shanghai Key Lab New Drug Design, State Key Lab Bioreactor Engn, Sch Pharm, Shanghai 200237, Peoples R China
基金
中国国家自然科学基金;
关键词
2-Thioxo-4-thiazolidinone; Peroxisome proliferator activated receptor gamma; Binding activities; SAR; Molecular docking; ACTIVATED RECEPTOR-GAMMA; TYPE-2; DIABETES-MELLITUS; BLADDER-CANCER; FATTY-ACIDS; PEROXISOME; RISK; LIGAND; THIAZOLIDINEDIONE; PIOGLITAZONE; TROGLITAZONE;
D O I
10.1016/j.cclet.2014.10.008
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We designed and synthesized a series of 2-thioxo-4-thiazolidinone derivatives and evaluated them on peroxisome proliferator activated receptor gamma (PPAR gamma) binding activities. Through the biological assays, compounds 18 and 38 were highlighted with K-i values of 12.15 nmol/L and 14.46 nmol/L, respectively. Then structure-activity relationship (SAR) was analyzed to screen privileged structural modifications. Moreover, molecular fitting of these compounds onto the approved drug Rosiglitazone in the PPAR gamma ligand binding domain was performed to elucidate the SAR and explore potential receptor-ligand interactions. These results demonstrate that the 2-thioxo-4-thiazolidinones can be considered as new promising molecular probes with excellent binding activities to PPAR gamma. (C) 2014 Rui Wang and Yu-Fang Xu. Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. All rights reserved.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 41 条
[1]   PPARγ signaling and metabolism: the good, the bad and the future [J].
Ahmadian, Maryam ;
Suh, Jae Myoung ;
Hah, Nasun ;
Liddle, Christopher ;
Atkins, Annette R. ;
Downes, Michael ;
Evans, Ronald M. .
NATURE MEDICINE, 2013, 19 (05) :557-566
[2]   The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study [J].
Azoulay, Laurent ;
Yin, Hui ;
Filion, Kristian B. ;
Assayag, Jonathan ;
Majdan, Agnieszka ;
Pollak, Michael N. ;
Suissa, Samy .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[3]   Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones [J].
Bruno, G ;
Costantino, L ;
Curinga, C ;
Maccari, R ;
Monforte, F ;
Nicolò, F ;
Ottanà, R ;
Vigorita, MG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (04) :1077-1084
[4]  
Caldwell SH, 2001, AM J GASTROENTEROL, V96, P519
[5]   PPAR: a therapeutic target in Parkinson's disease [J].
Chaturvedi, Rajnish K. ;
Beal, M. Flint .
JOURNAL OF NEUROCHEMISTRY, 2008, 106 (02) :506-518
[6]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]   Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation [J].
Chinetti, G ;
Fruchart, JC ;
Staels, B .
INFLAMMATION RESEARCH, 2000, 49 (10) :497-505
[8]   Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists [J].
Chittiboyina, Amar G. ;
Venkatraman, Meenakshi S. ;
Mizuno, Cassia S. ;
Desai, Prashant V. ;
Patny, Akshay ;
Benson, Stephen C. ;
Ho, Christopher I. ;
Kurtz, Theodore W. ;
Pershadsingh, Harrihar A. ;
Avery, Mitchell A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (14) :4072-4084
[9]   Risks of troglitazone apparent before approval in USA [J].
Cohen, JS .
DIABETOLOGIA, 2006, 49 (06) :1454-1455
[10]   Thiazolidinediones: a new class of antidiabetic drugs [J].
Day, C .
DIABETIC MEDICINE, 1999, 16 (03) :179-192